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Application of the H2FPEF
score to a global clinical trial
of patients with heart failure
with preserved ejection
fraction: the TOPCAT trial
Diagnostic uncertainties and lack of stan-
dardized strategies to enrich baseline risk
have posed significant challenges to the effec-
tive conduct of global trials of heart failure
with preserved ejection fraction (HFpEF).
Differences in event rates across regions in
the Treatment of Preserved Cardiac Func-
tion Heart Failure With an Aldosterone
Antagonist Trial (TOPCAT, NCT00094302)
underscore the importance of consistent
standards for HFpEF diagnosis.1 The recent
H2FPEF-score, which uses six routinely avail-
able clinical and echocardiographic variables,
is the first validated diagnostic algorithm
for identification of HFpEF in patients with
unexplained dyspnoea2 and offers promise
as a screening measure in clinical trials. The
TOPCAT trial presents a unique opportunity
to evaluate the application of this score in a
trial population with known background het-
erogeneity, and to understand its relationship
with risk of clinical events.
TOPCAT was a global, phase 3, double-
blind, placebo-controlled randomized clinical
trial of spironolactone in HFpEF enrolling
patients from the Americas (United States,
Canada, Brazil, Argentina), Russia, and the
Republic of Georgia.3 Eligible patients were
those ≥ 50 years with symptomatic HF and
left ventricular ejection fraction (EF) ≥ 45%,
well-controlled blood pressure, and a serum
potassium < 5.0 mmol/L as well as a recent
heart failure (HF) hospitalization within
12 months or elevated natriuretic peptide
(NP) concentrations within 60 days. In a
subset, pre-randomization echocardiograms
were submitted to a central core laboratory.4
The primary outcome was time to composite
hospitalization for HF, cardiovascular death,
or aborted cardiac arrest.
The H2FPEF score was developed from
a retrospective analysis of patients referred
for invasive haemodynamic exercise testing
for the evaluation of unexplained dyspnoea
at a tertiary care centre.2 Analyses in this
TOPCAT substudy were performed in 362
patients with available data necessary to
calculate the H2FPEF score: age, body mass
index, hypertension medication use, history
of atrial fibrillation, pulmonary artery sys-
tolic pressure (PASP, estimated from the
modified Bernoulli equation of the peak tri-
cuspid valve regurgitation velocity+ 5 mmHg
as a surrogate of right atrial pressure)
and E/e’.
We estimated diagnostic probabilities of
HFpEF reported in the original derivation
report of the H2FPEF score.
2 We assessed
the association between H2FPEF score and
baseline NP levels (either B-type NP or
N-terminal pro-B-type NP), which were
log-transformed and standardized (expressed
per 1 standard deviation; Z-score). Multi-
variable Cox proportional hazards models
were used to assess the association between
H2FPEF score and the primary composite
outcome. Restricted cubic splines models
with the number of knots selected based
on the lowest Akaike Information Criterion
were used to flexibly model the relationship
between H2FPEF score and standardized NPs
and the incidence of the primary endpoint. All
patients provided written informed consent,
and the study was approved by institutional
review board or ethics committees at each
participating institution. All statistical anal-
yses were performed using STATA 14.1
(StataCorp., College Station, TX, USA).
Of the 313 (18%) patients from the Amer-
icas and 49 (3%) from Russia/Georgia with
available data, the median H2FPEF score was
6 (interquartile range 4–7) and 5 (interquar-
tile range 3–6), respectively (P = 0.01 for
difference between regions) (Figure 1A), and
there were no differences between patients
enrolled by HF hospitalization or NP strata
(P = 0.83). Of the total 362 patients, 216
(60%) had body mass index > 30 kg/m2 (2
points), 344 (95%) used ≥ 2 antihypertensive
drugs (1 point), 177 (49%) had a history of
atrial fibrillation (paroxysmal or persistent,
3 points), 171 (47%) had PASP > 35 mmHg
(1 point), 315 (87%) were older than 60 years
(1 point), and 307 (85%) had E/e’ > 9 (1
point). Overall, 74% and 59% of patients had
H2FPEF scores ≥ 5 (corresponding to HFpEF
diagnostic probabilities of > 80%) in the
Americas and Russia/Georgia, respectively
(P = 0.026). Patients with higher scores were
more likely to be men, enrolled in the Ameri-
cas region, carry a history of diabetes mellitus,
have lower estimated glomerular filtration
rate and greater left atrial and left ventricular
volumes, in addition to parameters included
in the H2FPEF score (all P< 0.01) (Table 1).
There was a trend for greater concentrations
of NPs with higher H2FPEF score, although
this did not reach statistical significance
(P = 0.07) (Figure 1B).
Over a 2.7-year mean follow-up, 112
primary outcome events occurred. Higher
H2FPEF scores (per point) were associated
with increased risk of the primary outcome
[hazard ratio (HR) 1.12, 95% confidence
interval (CI) 1.02–1.23; P = 0.02] (Figure 1C).
Similar, yet not statistically significant, asso-
ciations between the H2FPEF score and the
primary endpoint were found in analysis
restricted to patients with left ventricu-
lar EF ≥ 50% (n = 319) (HR 1.09, 95% CI
0.98–1.21; P = 0.12). The incidence rate of
the primary outcome in patients with H2FPEF
score ≤ 4, 5–6, and ≥ 7 was 8.3 (95% CI
5.6–12.4), 11.8 (95% CI 8.7–16.0), and 13.7
(95% CI 10.2–18.3), respectively. The asso-
ciation between the H2FPEF score and the
primary endpoint did not differ by enrolment
strata (recent HF hospitalization or ele-
vated NP) (Pinteraction = 0.57). Higher H2FPEF
scores (per point) were also associated with
increased risk of HF hospitalization (HR 1.14,
95% CI 1.01–1.27; P = 0.03) and cardiovas-
cular death (HR 1.15, 95% CI 0.98–1.34;
P = 0.10) separately, although the latter asso-
ciation did not reach statistical significance.
HFpEF is a syndrome that is challenging
to differentiate from non-cardiac sources of
dyspnoea based on clinical examination alone.
Although invasive and/or exercise haemo-
dynamic assessments are available to affirm
the HFpEF diagnosis, cost, complexity, pro-
cedural risk, and limited availability preclude
their use in large clinical trials. In addition,
risk enrichment strategies applied in HFpEF
trials are subject to important limitations.
Thresholds for hospitalization for HF may
vary globally and across health systems.5
NP concentrations have traditionally been
used to identify HFpEF patients with greater
certainty and to enrich risk, however these
vary substantially and may be systematically
© 2019 The Authors








































































































































































































































Figure 1 Distribution of the H2FPEF score in the global TOPCAT trial, and its association with concentrations of natriuretic peptides and
the primary composite outcome. Overall, 362 patients had available data to calculate the H2FPEF score. (A) Distribution of scores in patients
enrolled in the Americas and Russia/Georgia. (B) Association between the H2FPEF score and log-transformed, standardized natriuretic pep-
tide concentrations as a continuous variable. (C) Association between the H2FPEF score and incidence of the primary composite endpoint.
Natriuretic peptide levels (either B-type natriuretic peptide or N-terminal pro-B-type natriuretic peptide) were log-transformed and standard-
ized (expressed per 1 standard deviation; Z-score). The primary outcome for the TOPCAT trial and for this analysis was time to composite
hospitalization for heart failure, cardiovascular death, or aborted cardiac arrest. The dotted lines reflect the 95% confidence interval.
lower in select populations (including black
and obese patients).6
In this study, we demonstrate that the
H2FPEF score correlates with increased
risk of adverse cardiovascular events in the
TOPCAT trial. Despite variation in analytic
approaches, another group recently inde-
pendently supported the prognostic value of
the H2FPEF score in TOPCAT.
7 We further
demonstrate that the H2FPEF score was only
partially and non-significantly associated with
NPs, suggesting that these two parameters
may provide orthogonal and incremental
information.
Among patients determined eligible for
enrolment in a large HFpEF trial, we observed
that 25% of patients in TOPCAT Americas
had diagnostic probabilities of HFpEF < 55%
as estimated by the H2FPEF score, while
41% of patients enrolled in TOPCAT Rus-
sia/Georgia fell into this lower diagnostic
probability. These findings are in keeping with
regional differences in event rates suggesting
a four-fold lower risk of the primary out-
come in Russia/Georgia as compared with
the Americas.1 When applied to a referral
cohort from Alberta, Canada, the discrimi-
natory value of the H2FPEF score was lower
than that observed in the original deriva-
tion and internal validation cohorts.8 Taken
together, these data emphasize the ongoing
need to understand the variability in distribu-
tion and performance of the H2FPEF score
across global, heterogeneous populations.
The study is subject to certain limita-
tions, including the restricted number of
patients with available data for H2FPEF score
calculation, which may introduce selection
bias. The H2FPEF score was derived from
a population of patients with unexplained
dyspnoea, while we applied it retrospectively
to patients deemed to have symptomatic
© 2019 The Authors








































































































































































































































Table 1 Baseline characteristics of patients in TOPCAT by categories of H2FPEF score (n = 362)
H2FPEF score
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
≤4 5 and 6 ≥7
(n = 100, 28%) (n = 130, 36%) (n = 132, 36%) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (years) 69.9± 11.2 70.7± 9.4 74.7± 8.7 <0.001
Male sex 34 (34.0%) 61 (46.9%) 68 (51.5%) 0.009
Black race 19 (19.0%) 33 (25.4%) 15 (11.4%) 0.09
Region 0.017
Russia and Georgia 20 (20.0%) 17 (13.1%) 12 (9.1%)
The Americas 80 (80.0%) 113 (86.9%) 120 (90.9%)
Eligibility criteria 0.64
Prior HF hospitalization in 12 months 61 (61.0%) 82 (63.1%) 77 (58.3%)
Elevated NP in 60 days 39 (39.0%) 48 (36.9%) 65 (41.7%)
NYHA class III or IV 41 (41.4%) 56 (43.4%) 63 (47.7%) 0.33
Hypertension 94 (94.0%) 118 (90.8%) 122 (92.4%) 0.71
Diabetes mellitus 35 (35.0%) 59 (45.4%) 59 (44.7%) 0.16
Previous myocardial infarction 22 (22.0%) 29 (22.3%) 31 (23.5%) 0.78
Previous cerebrovascular accident 12 (12.0%) 9 (6.9%) 17 (12.9%) 0.72
Peripheral artery disease 10 (10.0%) 19 (14.6%) 9 (6.8%) 0.35
History of atrial fibrillation 1 (1.0%) 44 (33.8%) 132 (100.0%) <0.001
Body mass index (kg/m2) 29.5± 8.2 34.0± 8.2 34.4± 7.4 <0.001
Waist circumference (cm) 98.7± 16.1 107.0±16.0 110.9±16.1 <0.001
Systolic blood pressure (mmHg) 128.5±16.6 125.4±16.3 123.7±15.0 0.025
eGFR (mL/min/1.73 m2) 65.8± 21.3 64.4± 20.9 59.7±18.1 0.018
N-terminal proBNP (ng/L) 791 [437–2054] 1068 [475–1615] 1354 [751–2023] 0.32
BNP (ng/L) 234 [155–698] 208 [130–375] 329 [165–568] 0.21
Baseline medication use
𝛽-blocker 76 (76.0%) 106 (81.5%) 102 (77.3%) 0.89
Calcium channel blocker 38 (38.0%) 63 (48.5%) 55 (41.7%) 0.67
Diuretic 81 (81.0%) 113 (86.9%) 123 (93.2%) 0.005
ACEi/ARB 72 (72.0%) 107 (82.3%) 109 (82.6%) 0.06
Aspirin 72 (72.0%) 82 (63.1%) 70 (53.0%) 0.003
Statin 66 (66.0%) 86 (66.2%) 89 (67.4%) 0.81
Baseline echocardiography
LV ejection fraction (%) 60.6± 8.1 60.1± 7.4 58.8± 7.9 0.07
LV mass index (g/m2) 104.8± 32.1 109.4± 26.7 109.5± 33.2 0.28
LV end diastolic volume index (mL/m2) 49.8± 15.9 49.3± 15.1 43.8±12.9 0.002
LA volume index (mL/m2) 29.1±10.9 31.4± 9.6 36.5±18.7 <0.001
E/e’ lateral ratio 12.4± 5.4 12.4± 6.6 13.1± 7.0 0.41
Pulmonary artery systolic pressure (mmHg) 35.7± 10.8 35.0± 11.0 40.1±11.4 0.002
Data are reported as n (%), mean± standard deviation, or median [quartile 1 to quartile 3].
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BNP, B-type natriuretic peptide; eGFR, estimated glomerular filtration rate; HF, heart
failure; LA, left atrial; LV, left ventricular; NYHA, New York Heart Association; NP, natriuretic peptide.
HFpEF by a site investigator in a random-
ized clinical trial. TOPCAT enrolled patients
with left ventricular EF ≥ 45%, which is
below accepted diagnostic cut-offs for
HFpEF; sensitivity analysis restricted to
patients with left ventricular EF ≥ 50% yields
directionally consistent, but non-significant
findings. Finally, it is uncertain whether its
prognostic value can be attributed to the
composite score or to individual component
elements.
Disease heterogeneity and diagnostic
uncertainty have long been concerns in
explaining the failures of previous HFpEF
trials. This simple score based on six rou-
tinely collected clinical and echocardiographic
variables represents an attractive option
as a risk enrichment strategy in enrolment
for future global clinical trials of HFpEF.
However, future prospective studies are
needed to externally validate this diagnostic
algorithm in larger samples, determine the
scope of its applicability in a broad range
of patients with dyspnoea syndromes, and
test its utility as a metric of clinical trial eli-
gibility and risk enrichment in HFpEF against
current strategies (prior hospitalization for
HF and NPs).
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